Advanced Endometrial Cancer
9
3
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.1%
1 terminated out of 9 trials
66.7%
-19.8% vs benchmark
22%
2 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
BKM120 as Second-line Therapy for Advanced Endometrial Cancer